Cell No. : Cell Name
RCB0689 : TCO-2
update : 2022/07/07
|
Comment | Human cell line derived from uterine cervix cancer. Adenocarcinoma. Said producing CEA, CA125, TPA. |
Comment from the depositor | |
Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
Remarks | |
Order Form |
Order Form(C-0005.pdf)
 
MTA(C-0007.pdf)
 
MTA(C-0007p.pdf)
 
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
Basic information
|
Depositor |
Izumi, Rikuichi
|
Originator |
Fushiki, Hiroshi
|
Year of deposit |
1991
|
Animal |
_human
< Mammals
|
Genus |
Homo
|
Species |
sapiens
|
Race |
Japanese
|
Gender |
Female
|
Age at sampling |
34 years
|
Tissue |
cervix, lymph node meta
|
Disease name |
uterine cervical adenocarcinom
|
Metastatic ability |
No
|
Classification |
cancer
|
Year of origin |
1987
|
Memo_1 |
Mycoplasma was eliminated with MC-210 by the depositor.
|
|
Lifespan |
infinite
|
Morphology |
other
|
Cellosaurus(Expasy) |
CVCL_3630
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
Culture medium |
|
MEM + 10% FBS
|
Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 4 split
|
SC frequency |
|
Subculture : once/week, Medium Renewal : 2 times/week
|
Temperature |
|
37
℃
|
CO2 concentration |
|
5
%
|
Freeze medium |
|
Medium + 10% DMSO
|
Freezing method |
|
Slow freezing
|
Mycoplasma |
|
(-)
|
Virus (HIV) |
|
(-)
|
Isozyme |
|
LD, NP
|
Chromosome mode |
|
45-93(50) : 45(7),46(38),47(1),90(1),92(3)
|
STR(human) |
|
OK
|
Images |
deposit info | lot info |
|
|
Reference information |
Reference |
1
|
User's Publication |
4
|
User's Publication |
14363
Takiguchi E, Nishimura M, Mineda A, Kawakita T, Abe A, Irahara M.
Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells
Exp Ther Med
2017
14(5):4293-4299
PubMed ID: 29067110
DOI: 10.3892/etm.2017.5061
|
6410
Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.
Is parainfluenza virus a threatening virus for human cancer cell lines?
Hum Cell
2009
22(3):81-4
PubMed ID: 19624309
DOI: 10.1111/j.1749-0774.2009.00071.x
|
2706
Harada H, Watanabe S, Saijo K, Ishiwata I, Ohno T
A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells.
Exp Hematol
2004
32:614-21
PubMed ID: 15246157
DOI: 10.1016/j.exphem.2004.03.011
|
2758
Harada, Hideki, Saijo, Kaoru, Watanabe, Satoru, Tsuboi, Koji, Nose, Tadao, Ishiwata, Isamu, Ohno, Tadao
Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT.
Jpn J Cancer Res
2002
93:313-9
PubMed ID: 11927014
DOI: 10.1111/j.1349-7006.2002.tb02174.x
|